Other analysts have also recently issued reports about the company. HC Wainwright dropped their price objective on SpringWorks Therapeutics from $142.00 to $95.00 and set a buy rating for the company in a report on Monday, June 6th. The Goldman Sachs Group lowered their price target on SpringWorks Therapeutics from $92.00 to $76.00 and set a buy rating for the company in a research note on Tuesday, May 24th.
SpringWorks Therapeutics stock opened at $25.60 on Monday. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -6.07 and a beta of 1.08. SpringWorks Therapeutics has a 12-month low of $13.60 and a 12-month high of $89.75. The stock has a 50-day simple moving average of $33.48 and a 200 day simple moving average of $50.38.
Hedge funds have recently made changes to their positions in the company. First Horizon Advisors Inc. grew its position in shares of SpringWorks Therapeutics by 330.1% in the 4th quarter. First Horizon Advisors Inc. now owns 443 shares of the company’s stock valued at $27,000 after purchasing an additional 340 shares during the period. Point72 Hong Kong Ltd acquired a new position in shares of SpringWorks Therapeutics in the 3rd quarter valued at approximately $33,000. Parallel Advisors LLC acquired a new position in shares of SpringWorks Therapeutics in the 4th quarter valued at approximately $47,000. Advisor Group Holdings Inc. grew its position in shares of SpringWorks Therapeutics by 93.7% in the 4th quarter. Advisor Group Holdings Inc. now owns 1,540 shares of the company’s stock valued at $95,000 after purchasing an additional 745 shares during the period. Finally, Fieldpoint Private Securities LLC grew its position in shares of SpringWorks Therapeutics by 102.4% in the 4th quarter. Fieldpoint Private Securities LLC now owns 1,619 shares of the company’s stock valued at $100,000 after purchasing an additional 819 shares during the period. 96.20% of the stock is owned by institutional investors.
About SpringWorks Therapeutics (Get Rating)
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.